GW&K Investment Management LLC lifted its stake in Alkermes plc (NASDAQ:ALKS - Free Report) by 259.6% during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,051,447 shares of the company's stock after buying an additional 759,060 shares during the quarter. GW&K Investment Management LLC owned approximately 0.63% of Alkermes worth $42,604,000 at the end of the most recent reporting period.
Several other hedge funds have also recently modified their holdings of ALKS. Dimensional Fund Advisors LP increased its holdings in Alkermes by 2.5% in the 1st quarter. Dimensional Fund Advisors LP now owns 4,522,378 shares of the company's stock valued at $159,850,000 after acquiring an additional 109,595 shares during the last quarter. Commodore Capital LP boosted its holdings in shares of Alkermes by 18.3% during the 1st quarter. Commodore Capital LP now owns 4,200,000 shares of the company's stock valued at $148,512,000 after purchasing an additional 650,000 shares during the last quarter. First Trust Advisors LP boosted its holdings in shares of Alkermes by 104.2% during the 1st quarter. First Trust Advisors LP now owns 2,968,785 shares of the company's stock valued at $104,976,000 after purchasing an additional 1,514,783 shares during the last quarter. Affinity Asset Advisors LLC boosted its holdings in shares of Alkermes by 35.0% during the 1st quarter. Affinity Asset Advisors LLC now owns 1,350,000 shares of the company's stock valued at $47,736,000 after purchasing an additional 350,000 shares during the last quarter. Finally, Public Sector Pension Investment Board grew its position in shares of Alkermes by 59.8% during the third quarter. Public Sector Pension Investment Board now owns 1,082,205 shares of the company's stock valued at $43,158,000 after purchasing an additional 404,800 shares in the last quarter. Hedge funds and other institutional investors own 95.21% of the company's stock.
Insider Transactions at Alkermes
In related news, EVP Craig Hopkinson sold 9,000 shares of Alkermes stock in a transaction that occurred on Tuesday, September 1st. The shares were sold at an average price of $46.99, for a total transaction of $422,910.00. Following the transaction, the executive vice president directly owned 65,389 shares of the company's stock, valued at $3,072,629.11. This trade represents a 12.10% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP David Gaffin sold 2,035 shares of the business's stock in a transaction that occurred on Tuesday, November 3rd. The stock was sold at an average price of $46.17, for a total transaction of $93,955.95. Following the completion of the transaction, the executive vice president directly owned 219,353 shares of the company's stock, valued at $10,127,528.01. This trade represents a 0.92% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 15,103 shares of company stock worth $697,973 in the last three months. Insiders own 4.59% of the company's stock.
Analyst Upgrades and Downgrades
ALKS has been the topic of a number of research reports. HC Wainwright lifted their price objective on Alkermes from $43.00 to $50.00 and gave the stock a "neutral" rating in a research note on Wednesday, November 4th. Wells Fargo & Company increased their target price on Alkermes from $65.00 to $68.00 and gave the company an "overweight" rating in a research report on Wednesday, November 4th. JPMorgan Chase & Co. raised their target price on shares of Alkermes from $60.00 to $61.00 and gave the company a "neutral" rating in a report on Wednesday, July 29th. TD Cowen reissued a "buy" rating on shares of Alkermes in a report on Monday, September 21st. Finally, Piper Sandler restated an "overweight" rating and issued a $65.00 price target (up from $43.00) on shares of Alkermes in a research report on Tuesday, July 28th. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, five have given a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $55.73.
Get Our Latest Stock Analysis on ALKS
Alkermes Trading Down 1.4%
NASDAQ ALKS opened at $46.18 on Friday. The stock has a market cap of $7.76 billion, a PE ratio of -2,307.85 and a beta of 0.32. Alkermes plc has a 12 month low of $27.00 and a 12 month high of $55.67. The company's 50-day moving average price is $43.71 and its 200-day moving average price is $41.37. The company has a current ratio of 2.42, a quick ratio of 2.02 and a debt-to-equity ratio of 0.79.
Alkermes (NASDAQ:ALKS - Get Free Report) last issued its earnings results on Wednesday, November 4th. The company reported $0.09 earnings per share for the quarter, topping the consensus estimate of ($0.08) by $0.17. The business had revenue of $480.13 million during the quarter, compared to analysts' expectations of $463.48 million. Alkermes had a positive return on equity of 0.40% and a negative net margin of 0.02%. The business's revenue for the quarter was up 21.8% compared to the same quarter last year. During the same period in the prior year, the business earned $0.49 EPS. Equities research analysts forecast that Alkermes plc will post -0.52 earnings per share for the current year.
About Alkermes
(
Free Report)
Alkermes plc is a biopharmaceutical company focused on developing and commercializing medicines for neuroscience-related conditions, including serious mental illness and addiction. Founded in 1987, the company has operations in the United States and Ireland, with its corporate headquarters in Dublin and major U.S. operations in Massachusetts. Its marketed medicines include Vivitrol, an extended-release injectable formulation of naltrexone used to treat alcohol dependence and to prevent relapse to opioid dependence after detoxification; Aristada, an injectable treatment for schizophrenia in adults; and Lybalvi, a medicine for schizophrenia and bipolar I disorder in adults.
Featured Articles
Want to see what other hedge funds are holding ALKS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alkermes plc (NASDAQ:ALKS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Alkermes, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alkermes wasn't on the list.
While Alkermes currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.